Patents Assigned to Inserm
  • Diagnostic of heart failure
    Patent number: 11061037
    Abstract: Disclosed herein is a method for classifying a patient at risk for heart failure, wherein the method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from the patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the concentration of IGFBP2 in samples from patients who are at particular stages of heart failure and/or to a control value derived from the concentration of IGFBP2 in blood samples from healthy patients.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 13, 2021
    Assignees: INSERM (INSTITUT DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Philippe Rouet, Fatima Smih-Rouet, Franck Desmoulin, Michel Galinier
  • Methods for predicting acute severe colitis treatment response
    Patent number: 11060147
    Abstract: The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: July 13, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE-HOPPITAUX DE PARIS (APHP), UNIVERSITE DE BORDEAUX, CHU DE BORDEAUX, UNIVERSITE PARIS XIII PARIS-NORD
    Inventors: Eric Ogier-Denis, Xavier Treton, Yoram Bouhnik, Ian Morilla, David Laharie, Gilles Wainrib, Mathieu Uzzan
  • IMMUNOGENIC PRODUCT COMPRISING IL-4 AND/OR IL-13 FOR TREATING DISORDERS ASSOCIATED WITH ABERRANT IL-4 AND/OR IL 13 EXPRESSION OR ACTIVITY
    Publication number: 20210205427
    Abstract: An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.
    Type: Application
    Filed: May 29, 2019
    Publication date: July 8, 2021
    Applicants: NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR
    Inventors: Géraldine GROUARD-VOGEL, Eva CONDE GARCÌA, Romain BERTRAND, Noémie CAILLOT, Laurent REBER, Pierre BRUHNS, Vincent SERRA
  • RAAV WITH CHEMICALLY MODIFIED CAPSID
    Publication number: 20210205467
    Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.
    Type: Application
    Filed: February 10, 2021
    Publication date: July 8, 2021
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Mathieu MEVEL, David DENIAUD, Eduard AYUSO
  • Methods and pharmaceutical compositions for the treatment of kidney cancer
    Patent number: 11052131
    Abstract: Disclosed are methods and pharmaceutical compositions for the treatment of kidney cancer. The inventors showed that while Elabela (ELA) is mostly expressed in kidney, its expression is reduced in human kidney cancer. In a xenograft animal model (sub-cutaneous, or sub-capsular injection) Ela inhibits tumor progression. In particular, there is disclosed a method of treating kidney cancer in a subject in need thereof including administering to the subject a therapeutically effective amount of an ELA polypeptide including an amino acid sequence having at least 90% of identity with SEQ ID NO: 1 (QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP) wherein the arginine residue (R) at position 9, 10, 20 or 21 is optionally mutated.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: July 6, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE BORDEAUX, INSTITUT BERGONIÉ
    Inventors: Géraldine Siegfried, Abdel-Majid Khatib, Jean-Luc Hoepffner, Serge Evrard
  • METHODS AND DEVICES FOR FULL-FIELD OCULAR BLOOD FLOW IMAGING
    Publication number: 20210196120
    Abstract: According to a first aspect, the present disclosure relates to a digital holography device (100) for full-field blood flow imaging of ocular vessels of a field of view of a layer (11) of the eye (10). The device comprises an optical source (101) configured for the generation of an illuminating beam (Eobj) and a reference beam (ELO), and a detector (135) configured to acquire a plurality of interferograms (I(x,y,t)) wherein an interferogram is defined as the signal resulting from the interference between the said reference beam (ELO) and a part of said illuminating beam (Eobj) that is backscattered from said layer (11).
    Type: Application
    Filed: December 30, 2019
    Publication date: July 1, 2021
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE SUPÉRIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), SORBONNE UNIVERSITE
    Inventors: Léo Puyo, Michael Atlan
  • Derivatives of porphyrins, their process of preparation and their use for treating viral infections
    Patent number: 11046704
    Abstract: The present invention concerns metallated porphyrin derivatives as ligands of G-quadruplex and their novel use as anti-viral agents.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: June 29, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉDE BORDEAUX
    Inventors: Samir Amrane, Marie-Aline Andreola, Geneviève Pratviel, Jean-Louis Mergny
  • Method for laser printing biological components, and device for implementing said method
    Patent number: 11045996
    Abstract: A method for printing uses at least one bio-ink. The method also uses at least one laser print head to deposit at least one droplet of at least one bio-ink onto a depositing surface of a receiving substrate. The printing method uses at least one nozzle print head to deposit at least one droplet of at least one bio-ink onto a depositing surface of the same receiving substrate as the laser print head.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: June 29, 2021
    Assignees: Universite de Bordeaux, Institut National de la Sante et de la Recherche Medicale—Inserm
    Inventor: Fabien Guillemot
  • METHOD OF CULTURING PROLIFERATIVE HEPATOCYTES
    Publication number: 20210189346
    Abstract: A method of culturing animal cells, preferably primary hepatocytes, including a first step of culturing the animal cells in non-adherent culture vessel, preferably a low or ultra-low attachment culture vessel, a second step of embedding the animal cells in a collagen matrix or in a gelatin matrix, and a third step of culturing the animal cells embedded in the collagen matrix or in the gelatin matrix, thereby obtaining 3D animal cell structures including proliferative animal cells, preferably spheroids including proliferative primary hepatocytes. Also, a spheroid including proliferative primary hepatocytes and the uses thereof for engineering an artificial liver model or an artificial liver organ, and for assessing in vitro the liver toxicity, genotoxicity and/or the effects of a drug or a compound.
    Type: Application
    Filed: May 16, 2019
    Publication date: June 24, 2021
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE RENNES 1, ÉCOLE DES HAUTES ÉTUDES EN SANTÉ PUBLIQUE (EHESP)
    Inventors: Georges BAFFET, Sophie LANGOUET, Frédéric EZAN, Sophie ROSE, Marie CUVELLIER
  • Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with Friedreich ataxia
    Patent number: 11040113
    Abstract: The present invention relates to a vector which comprises a nucleic acid sequence encoding for the frataxin (FXN) gene for use in the prevention and treatment of neurological phenotype associated with Friedreich ataxia in a subject in need thereof.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: June 22, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique (CNRS), Université de Strasbourg
    Inventors: Hélène Puccio, Françoise Piguet
  • Polypeptides comprising vinculin binding sites for the treatment of proliferation and/or adhesion related diseases
    Patent number: 11040083
    Abstract: Disclosed are polypeptides including at least one vinculin binding sites, to nucleic acid sequences encoding thereof and to their use for treating a proliferation and/or adhesion related disease.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: June 22, 2021
    Assignees: PARIS SCIENCES ET LETTRES—QUARTER LATIN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE AL RECHERCHE MÉDICALE)
    Inventors: Guy Tran Van Nhieu, Cesar Valencia-Gallardo, Nicole Quenech'Du
  • Bacteriophage strain capable of producing a lytic infection in the ST131-025B:H4 clone
    Patent number: 11041147
    Abstract: The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of ST131-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes ST131-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: June 22, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS DIDEROT—PARIS 7, UNIVERSITÉ PARIS XIII PARIS-NORD
    Inventors: Jean-Damien Ricard, Olivier Clermont, Laurent Debarbieux, Erick Denamur, Nicolas Dufour
  • Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
    Patent number: 11040052
    Abstract: The present invention provides novel methods for the modulation of autophagy and the treatment of autophagy-related diseases, including cancer, neurodegenerative diseases, liver diseases, muscle diseases and pancreatitis.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: June 22, 2021
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Guido Kroemer, Guillermo Marino, Federico Pietrocola
  • CALCIUM-CHELATING PEPTIDES DERIVED FROM EF-HAND CALCIUM-BINDING MOTIF
    Publication number: 20210179682
    Abstract: The disclosure pertains to the field of molecular means capable of binding calcium, in particular peptides which are calcium chelators, appropriate for use in vitro or in vivo and preferably capable of targeting specific cellular compartments. Polypeptide comprising a first calcium-binding domain, a peptide linker and a second calcium binding domain, wherein the first and second binding domains are linked through the peptide linker, and wherein: the first calcium-binding domain and the second calcium binding domain each comprise at least one calcium-binding site derived from a EF-hand motif; and, the first calcium-binding domain and the second calcium binding domain differ in at least one calcium-binding site.
    Type: Application
    Filed: November 2, 2018
    Publication date: June 17, 2021
    Applicants: SORBONNE UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Xavier Nicol, Oriol Ros Torres
  • LIPOSOMAL FORMULATION OF BACTERIAL LIPOPOLYSACCHARIDE COMBINED WITH A CYTOTOXIC AGENT, AND USE THEREOF IN ANTI-TUMOUR THERAPY
    Publication number: 20210177755
    Abstract: The present invention relates to a pharmaceutical combination product comprising: a liposomal formulation exclusively containing a LPS; and at least one cytotoxic compound. It also relates to its use as an anti-tumour therapy.
    Type: Application
    Filed: October 30, 2018
    Publication date: June 17, 2021
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Léon Bérard
    Inventors: Charles DUMONTET, Abdelkamel CHETTAB
  • METHOD FOR GENERATING T CELLS PROGENITORS
    Publication number: 20210169934
    Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 10, 2021
    Applicants: Assistance Publique - Hopitaux de Paris, Fondation Imagine - Institut des Maladies Génétiques, Université de Paris, Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Isabelle André, Marina Cavazzana, Kuiying Ma, John Tchen
  • METHOD FOR GENERATING T CELLS PROGENITORS
    Publication number: 20210169935
    Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 10, 2021
    Applicants: Assistance Publique - Hopitaux de Paris, Fondation Imagine - Institut des Maladies Génétiques, Université de Paris, Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Isabelle André, Marina Cavazzana, Kuiying Ma, John Tchen
  • Novel Hydrazone Derivatives For Preventing Or Treating EBV-Related Cancers
    Publication number: 20210161887
    Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.
    Type: Application
    Filed: April 3, 2019
    Publication date: June 3, 2021
    Applicants: Universite de Bretagne Occidentale, Centre Hospitalier Regional Universitaire de Brest, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Institut Curie, Université de Paris, Univ Paris XIII Paris-Nord Villetaneuse, Universite Paris-Saclay
    Inventors: Marc Blondel, Alicia Quillevere, Cécile Voisset, Maria José Lista, Robin Fahraeus, Chrysoula Daskalogianni, Rodrigo Prado-Martins, Marie-Paule Teulade-Fichou, Anton Granzhan, Claire Beauvineau, Oksana Reznichenko
  • TREATMENT OF MONOGENIC DISEASES WITH AN ANTI-CD45RC ANTIBODY
    Publication number: 20210163593
    Abstract: Anti-CD45RC antibodies, for use in the treatment of monogenic diseases caused by genes not associated with immune function but whose deficiency is associated with inflammation and/or immune reactions (such as genes deficient in Duchenne muscular dystrophy (DMD), cystic fibrosis, lysosomal diseases and al-anti-trypsin deficiency); or caused by genes involved in the immune system and whose deficiency generates inflammation and/or autoimmune reactions (such as genes deficient in T-cell primary immunodeficiencies such as IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked syndrome), APECED (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy), B cell primary immunodeficiencies, Muckle-Wells syndrome, mixed autoinflammatory and autoimmune syndrome, NLRP12-associated hereditary periodic fever syndrome, and tumor necrosis factor receptor 1 associated periodic syndrome).
    Type: Application
    Filed: December 14, 2018
    Publication date: June 3, 2021
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, UNIVERSITÉ DE NANTES
    Inventors: Carole GUILLONNEAU, Ignacio ANEGON
  • AQUEOUS EXTRACT OF GROUND MATERIAL OF PLANARIAN ORGANISMS
    Publication number: 20210161973
    Abstract: The present invention relates to an aqueous extract useful notably for the regeneration of human or animal cells, notably mammalian cells, comprising an aqueous extract free of any insoluble solid debris of ground planarian organisms having a regeneration capacity, containing at least the intracellular components of the cells of said organisms of a cell lysate of said cells of said organisms.
    Type: Application
    Filed: May 30, 2018
    Publication date: June 3, 2021
    Applicants: FONDATION MEDITERRANEE INFECTION, UNIVERSITE D'AIX MARSEILLE, ASSISTANCE PUBLIQUE - HOPITAUX DE MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Eric GHIGO, Eric CHABRIERE, Michel DRANCOURT, Vincent BONNIOL